Drug Trial Radar · NCT05814666
Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
Last checked: Nov 19, 2026Latest source record: Jan 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
69
Actual
Start
May 30, 2023
Primary completion
Aug 14, 2025
Study completion Aug 14, 2025
Sponsor
- Lead sponsor
- Flamingo Therapeutics NVIndustry
- Sponsor type
- Industry
- First posted
- Apr 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Open-label, Phase II, randomized, controlled study evaluating the efficacy and safety of danvatirsen in combination with pembrolizumab compared with pembrolizumab alone as first-line treatment of patients with recurrent/metastatic (R/M) HNSCC. Two-thirds of patients will be randomized to receive danvatirsen and pembrolizumab and one-third will be randomized to receive pembrolizumab alone.
Conditions
- HNSCC
Interventions
DanvatirsenDrug
Danvatirsen is a STAT3 targeting drug.
PembrolizumabDrug
Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Confirmed ORRTime frame: Up to 18 months
Locations
32 sites in 3 countries. Site status is shown where the registry gives one.
The University of Arizona Cancer Center
Tucson, Arizona
University of California Irvine (UCI)
Irvine, California
TMPN Hunt Cancer Care
Torrance, California
University of California Los Angeles
Westwood, Los Angeles, California
University of Colorado Hospital (UCH) Anschutz Cancer Pavilion
Aurora, Colorado
Miami Cancer Institute
Miami, Florida
Emory University Hospital Midtown
Atlanta, Georgia
University of Illinois Cancer Center
Chicago, Illinois
AMR Kansas City Oncology
Merriam, Kansas
University of Kansas Medical Center
Westwood, Kansas
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana
University of Maryland Baltimore, Greenebaum Comprehensive Cancer Center
Baltimore, Maryland
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Morristown Medical Center
Morristown, New Jersey
Mount Sinai
New York, New York
Stony Brook Cancer Center
Stony Brook, New York
The Christ Hospital Cancer Center
Cincinnati, Ohio
University of Cincinnati Medical Center
Cincinnati, Ohio
University Hospitals Cleveland
Cleveland, Ohio
Prisma Health Cancer Institute
Greenville, South Carolina
UT Southwestern Medical Center/Simmons Comprehensive Cancer Center
Dallas, Texas
Dong-A University Hospital
Busan, South Korea
Kosin University College of Medicine - Kosin University Gospel Hospital (KUGH)
Busan, South Korea
Gyeongsang National University Hospital
Jinju, South Korea
Korea University Medical Center (KUMC)
Seoul, South Korea
The Catholic University of Korea - Eunpyeong St. Mary's Hospital
Seoul, South Korea
Saint James's University Hospital (SJUH) - St James's Institute of Oncology
Leeds, United Kingdom
The Clatterbridge Cancer Centre NHS Foundation Trust
Liverpool, United Kingdom
Barts Health MHS Trust (Barts and The London NHS Trust) - St Bartholomew's (Barts) Hospital
London, United Kingdom
The Royal Marsden NHS Foundation Trust
London, United Kingdom
East and North Hertfordshire NHS Trust, Lister Hospital
Northwood, United Kingdom
The Royal Marsden NHS Foundation Trust
Sutton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.